- Home
- RGEN
RGEN
Repligen Corporation
as 06-30-2025 1:33pm EST
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
| Founded: | 1981 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 8.0B | IPO Year: | N/A |
| Target Price: | $170.40 | AVG Volume (30 days): | 787.0K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $102.97 - $182.52 | Next Earning Date: | 07-29-2025 |
| Revenue: | $650,429,000 | Revenue Growth: | 4.88% |
| Revenue Growth (this year): | 13.93% | Revenue Growth (next year): | 14.35% |
Stock Insider Trading Activity of Repligen Corporation (RGEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hunt Anthony | RGEN | Director | May 15 '25 | Sell | $124.55 | 26,447 | $3,271,687.92 | 134,258 |
Latest Repligen Corporation News
RGEN Breaking Stock News: Dive into RGEN Ticker-Specific Updates for Smart Investing
Argus Research
6 days ago
RGEN: Raising target price to $99.00
StockStory
6 days ago
5 Insightful Analyst Questions From Repligen’s Q1 Earnings Call
Argus Research
20 days ago
RGEN: Raising target price to $140.00
StockStory
21 days ago
1 Unprofitable Stock for Long-Term Investors and 2 to Ignore
Simply Wall St.
a month ago
Three Stocks That May Be Trading Below Their Intrinsic Value In June 2025
StockStory
a month ago
Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks
StockStory
a month ago
Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers
Zacks
a month ago
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?
Compare RGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGEN Repligen Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.